LBI-HTA - Publications - Search - Year: 2011
Number of items: 35.

Patera, N. and Warmuth, M. (2011): Training therapy in physical medicine: Rapid systematic review. Decision Support Document 51.

Nachtnebel, A. and Püntmann, I. (2011): Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration resistant prostate cancer after docetaxel therapy. DSD: Horizon Scanning in Oncology 20.

Schumacher, I. and Warmuth, M. (2011): Exercise therapy (Krankengymnastik/Heilgymnastik) in physical medicine: Rapid systematic review. Decision Support Document 52.

Nachtnebel, A. (2011): Rituximab (Rituxan®/MabThera®)for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011. DSD: Horizon Scanning in Oncology 04 / Update 2011.

Patera, N. (2011): Quality of care in oncology and its measurement. HTA-Projektbericht 49a.

Gugerbauer, J. and Warmuth, M. (2011): Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases. Decision Support Document 049.

Radlberger, P. and Zechmeister, I. (2011): IFEDH - Innovative Framework for Evidence-based Decisionmaking in Health Care – Standardised working in HTA (WP 1.2). HTA-Projektbericht 044a.

Hintringer, K. (2011): Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011. DSD: Horizon Scanning in Oncology 11 / Update 2011.

Nachtnebel, A. (2011): Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011. DSD: Horizon Scanning in Oncology 06 / Update 2011.

Warmuth, M. and Schumacher, I. and Maringer, B. (2011): Efficacy and safety of treatment options for varicose veins. HTA-Projektbericht 051.

Hepperger, C. and Nachtnebel, A. (2011): S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer. DSD: Horizon Scanning in Oncology 19.

Piso, B. and Tüchler, H. (2011): Outpatient cardiac rehabilitation part IV: Options für a prospective study. Decision Support Document 048.

Warmuth, M. and Schumacher, I. (2011): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation . Decision Support Document 44.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. German version. Decision Support Document 47.

Wegman, M. and Thomas, S. and Deuber, HJ. (2011): Renal denervation in patients with essential hypertonia. Decision Support Document 45.

Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. English version. Decision Support Document 43.

Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. German version. Decision Support Document 43.

Gottardi, R. and Wild, C. (2011): Percutaneous aortic valve replacement (with a side note on hybrid operating rooms). Decision Support Document 18/Update 2011.

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version. Decision Support Document 47.

Mathis, S. and Johansson, T. and Mad, P. and Mittermayr, T. (2011): Mechanical percutaneous transluminal cerebral clot retrieval devices in acute ischemic stroke: Systematic Review on efficacy and safety. Decision Support Document 46.

Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.

Gerdvilaite, J. and Nachtnebel, A. (2011): Disinvestment. Overview of disinvestment experiences and challenges in selected countries. HTA-Projektbericht 57.

Fischer, S. and Zechmeister, I. (2011): Sacral Nerve Stimulation for Fecal Incontinence. Rapid Assessment 004.

Piso, B. and Wild, C. and Winkler, R. and Warmuth, M. (2011): Reorientation of the Austrian parent-child preventive care programme. Part IV: Synthesis of parts I-III, recommendations. HTA-Projektbericht 045d.

Warmuth, M. and Mad, P. and Piso, B. and Schumacher, I. and Wild, C. (2011): Reorientation of the Austrian parent-child preventive care programme. Part I: Epidemiology - Frequency of risk factors and disease during pregnancy and early childhood. HTA-Projektbericht 045a.

Winkler, R. (2011): Reorientation of the Austrian parent-child preventive care programme. Part II: International policies, concepts and screening strategies focusing on “normal” and “high-risk” development processes during pregnancy and early childhood until school entry. HTA-Projektbericht 045b.

Zechmeister, I. and Loibl, T. (2011): Reorientation of the Austrian parent-child preventive care programme. Part III: Financing structures of services and public transfers for parents and young children. HTA-Projektbericht 045c.

Hintringer, K. (2011): Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 17.

Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.

Schumacher, I. and Zechmeister, I. (2011): Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey. HTA-Projektbericht 37b.

Blagojevic, S. and Hinterreiter, G. and Wild, C. (2011): Annual Report 2010. English version.

Patera, N. (2011): Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research. HTA-Projektbericht 48.

Hintringer, K. (2011): Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 15.

Hinterreiter, G. and Wild, C. (2011): Annual Report 2010. German Version.

Nachtnebel, A. (2011): Ipilimumab for pre-treated patients with advanced/metastatic melanoma . DSD: Horizon Scanning in Oncology 14.

This list was generated on Tue Sep 26 03:00:05 2017 CEST.